Evolent Health Reaffirms 2025 Revenue and EBITDA Guidance

The latest update is out from Evolent Health ( (EVH) ).

On June 3, 2025, Evolent Health‘s management will present at the William Blair 45th Annual Growth Stock Conference, reaffirming its 2025 revenue guidance of $2.06 billion to $2.11 billion and Adjusted EBITDA guidance of $135.0 million to $165.0 million. The company also expects to reaffirm its second quarter 2025 revenue guidance of $440.0 million to $470.0 million and Adjusted EBITDA guidance of $33.0 million to $40.0 million, consistent with previous guidance. Evolent Health highlights the challenges in reconciling non-GAAP Adjusted EBITDA to net income due to various adjustments related to non-core operations and other factors.

The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.

Spark’s Take on EVH Stock

According to Spark, TipRanks’ AI Analyst, EVH is a Neutral.

Evolent Health demonstrates robust revenue growth and strategic expansions, yet faces challenges in profitability and cash management. Technical indicators suggest bearish trends, and the negative P/E ratio reflects ongoing unprofitability. The positive earnings call provides some optimism but is countered by financial risks and valuation concerns.

To see Spark’s full report on EVH stock, click here.

More about Evolent Health

Evolent Health, Inc. operates in the healthcare industry, offering services that support healthcare providers and payers in transitioning to value-based care. The company focuses on improving clinical and financial outcomes through its technology and services platform.

Average Trading Volume: 2,378,654

Technical Sentiment Signal: Sell

Current Market Cap: $888.7M

For a thorough assessment of EVH stock, go to TipRanks’ Stock Analysis page.